Inscription Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Inscription Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232K	Buy	520 +47	+10%	+$21.9K	0.02%	570
2025 Q4	$214K	Sell	473 -147	-24%	-$63.4K	0.02%	590
2025 Q3	$243K	Sell	620 -21	-3%	-$8.78K	0.03%	525
2025 Q2	$285K	Buy	641 +79	+14%	+$36.4K	0.04%	373
2025 Q1	$235K	Buy	+562	New	+$262K	0.04%	290
2024 Q3	$385K	Sell	827 -10	-1%	-$4.8K	0.06%	228
2024 Q2	$392K	Buy	837 +275	+49%	+$119K	0.06%	213
2024 Q1	$235K	Hold	562	–	–	0.04%	290
2023 Q4	$229K	Buy	+562	New	+$208K	0.06%	191

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Inscription Capital's VRTX Position: Q1 2026 in Review

Inscription Capital increased its Vertex Pharmaceuticals (VRTX) stake by 9.9% in Q1 2026, buying an estimated $21.9K and bringing the position to 520 shares worth $232K. The position accounts for 0.02% of the portfolio, ranked #570.

Inscription Capital first reported a position in VRTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $392K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Inscription Capital held 520 shares of Vertex Pharmaceuticals worth $232K as of Q1 2026.
Inscription Capital bought 47 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21.9K.
Vertex Pharmaceuticals made up 0.02% of Inscription Capital's portfolio in Q1 2026, its #570 holding.
Inscription Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Inscription Capital's Vertex Pharmaceuticals position peaked at $392K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.